Choosing a stem cell clinic is one of the most consequential medical decisions a patient can make — and the difference between a legitimate provider and a dangerous operator often comes down to a handful of recognizable warning signs. This guide details the red flags that have been documented in peer-reviewed literature and regulatory actions, so you can recognize them before it is too late.

Why Clinic Selection Matters: What Is at Stake

Stem cell therapy occupies a unique position in modern medicine. Unlike pharmaceuticals — which undergo years of clinical trials and receive formal marketing authorization — cell-based treatments in many jurisdictions fall under practice-of-medicine exemptions. This means a physician can legally administer cell therapy without the same regulatory oversight that governs a new drug. The result is an industry where quality varies enormously: ISO-certified hospital laboratories at one end, unlicensed operators at the other. [1]

A 2021 systematic review identified over 1,100 clinics in the United States alone marketing unproven stem cell interventions directly to consumers — and the global numbers are far larger. For patients, the consequences of choosing wrong range from wasted money to serious harm: infections, tumor formation, blindness, and death have all been documented following unapproved treatments. [2] [3]

The good news is that legitimate clinics are identifiable. High-quality stem cell providers share common, verifiable characteristics. They welcome scrutiny, publish their credentials, and can answer every question in this guide without hesitation. Learning to recognize these markers is the single most important step a prospective patient can take.

Key principle: A legitimate clinic does not ask you to trust it — it gives you the tools to verify it. Every credential, certification, and quality metric discussed below should be independently confirmable.

Step 1: Verify the Treating Physician

The single most important factor in your safety is the physician directing your care. In a legitimate stem cell clinic, a licensed physician specialist conducts your consultation, reviews your complete medical history, designs your personalized treatment protocol, oversees the cell administration, and remains responsible for your follow-up. The physician should be present during your procedure and available afterward. [4]

What to look for: The physician should hold a current, unrestricted medical license in the country where treatment is delivered. Ask for the full name, license number, and issuing medical council. Cross-check this information on the council's public registry. Most national medical councils — including the Thai Medical Council (แพทยสภา) — maintain online license-verification databases that are freely accessible.

Beyond licensure, look for specialty board certification relevant to regenerative medicine — fields such as orthopedics, neurology, immunology, sports medicine, or anti-aging and regenerative medicine. Board certification indicates advanced training and a commitment to ongoing education. The physician should also have several years of experience specifically in cell-based therapies, not just a general medical background. [5]

Red flag: If you never meet a physician — if your entire interaction is with a sales representative or coordinator — walk away. The person administering your treatment should be the same person who assessed your candidacy.

Step 2: Examine Laboratory Standards and Accreditation

The quality of your cells depends entirely on the quality of the laboratory that processes them. MSC manufacturing is a complex biological process requiring specialized facilities, trained personnel, and rigorous quality-control systems. A legitimate clinic operates — or partners with — a laboratory that meets internationally recognized standards. [6]

What to look for: The gold standard in laboratory quality management is ISO certification. Specifically, look for ISO 9001:2015 (quality management systems) and ISO/IEC 17025:2017 (testing and calibration laboratory competence). These certifications are issued by accredited national bodies — not self-declared — and carry certificate numbers you can verify on the issuing body's public registry.

In cell therapy manufacturing, the most relevant quality framework is Good Manufacturing Practice (GMP). A GMP-compliant laboratory operates under documented procedures for every step: donor screening, tissue processing, cell culture, sterility testing, cryopreservation, and final release. GMP certification means the facility has been inspected by a regulatory authority and found to meet standards for pharmaceutical-grade production. [7]

How to verify: Ask the clinic for the laboratory's accreditation certificate numbers and the names of the issuing bodies. Look them up independently. A legitimate clinic will provide this information without hesitation; an operator with something to hide will deflect, offer vague reassurances, or claim the information is "proprietary." Accreditation is a matter of public record — there is no legitimate reason to withhold it.

Step 3: Understand the Cell Source and Quality Metrics

Not all "stem cells" are the same — not even close. Mesenchymal stem cells can be sourced from bone marrow, adipose tissue, umbilical cord tissue (Wharton's jelly), dental pulp, and other tissues. Each source has different biological properties, proliferative capacity, and therapeutic profiles. A legitimate clinic can explain exactly what cell type it uses, where the cells come from, and why that source was chosen for your specific condition. [8]

What to look for: Request a written cell specification document — ideally a Certificate of Analysis for the specific batch intended for your treatment. This document should include:

If a clinic cannot produce a Certificate of Analysis — or dismisses the request as unnecessary — you cannot verify what is being injected into your body. That alone is disqualifying. [10]

Important: Some clinics market amniotic fluid or cord blood products as "stem cell therapy" despite these products containing few or no viable MSCs. The Certificate of Analysis — specifically the viable MSC count — is the only reliable way to distinguish real cell therapy from a mislabeled biological product.

Step 4: Evaluate the Treatment Protocol — Is It Personalized?

MSC therapy is not one-size-fits-all. The optimal cell dose, delivery route, and adjuvant protocol depend on the specific condition being treated, its severity, the patient's age, and their overall health status. A clinic that administers the same IV infusion of the same cell dose to every patient — regardless of whether they have knee osteoarthritis or an autoimmune disease — is not practicing personalized medicine. [11]

What to look for: During your consultation, the physician should discuss why a particular delivery route is recommended for your condition. Intravenous delivery may be appropriate for systemic inflammatory or autoimmune conditions, while intra-articular injection targets localized joint pathology. Intrathecal delivery, used for certain neurological indications, carries higher risk and requires specialized expertise. The rationale for the chosen route should be explained in terms of published evidence. [12]

The cell dose should also be condition-specific. Doses in published clinical trials range from approximately 1 million to over 200 million MSCs per kilogram of body weight, depending on the indication. A physician who cannot explain the scientific basis for the recommended dose is operating from a protocol template, not from medical reasoning.

Ask: "Why this dose? Why this delivery route? What published evidence supports these choices for my condition?" The answers — or the inability to provide them — will tell you a great deal about the quality of care you will receive.

Step 5: Examine Pricing and Financial Transparency

Quality MSC therapy is expensive to produce — but price alone is not a reliable quality indicator. The production cost of GMP-grade MSCs includes donor screening, cleanroom maintenance, culture media, growth factors, sterility testing, cryopreservation, physician expertise, and facility overhead. Legitimate treatment costs typically range from USD 8,000 to USD 25,000 depending on condition complexity, cell dose, and protocol specifics. [13]

What to look for: Transparent, itemized pricing. Before committing, you should receive a written breakdown that identifies the cost of the cell product itself, physician fees, facility fees, pre-treatment diagnostics, and follow-up assessments. Vague pricing — "the treatment package is USD 15,000" without detail — means you cannot evaluate what you are actually paying for.

Be extremely cautious of clinics offering stem cell therapy for USD 1,000–3,000. At that price point, the cost of GMP-grade cells alone — let alone physician time, testing, and facility overhead — cannot be covered. You are unlikely to receive what is being advertised. [14]

Equally, a price of USD 50,000+ does not automatically signal superior quality. Some clinics inflate prices to create a perception of premium care while delivering the same cell product available elsewhere for a fraction of the cost. The sweet spot combines mid-range pricing with full line-item transparency.

Price Range (USD)What to Expect
$1,000 – $3,000Likely diluted or non-viable product; avoid
$3,000 – $8,000Possibly quality cells but minimal physician involvement; verify carefully
$8,000 – $25,000Expected range for legitimate GMP-grade MSC therapy with physician oversight
$25,000+Complex protocols, multiple doses, or premium facilities; verify itemization

Step 6: Evaluate Follow-Up and Outcome Tracking

Responsible regenerative medicine does not end on treatment day — it begins a structured follow-up process that continues for months. A legitimate clinic schedules follow-up assessments at defined intervals — typically 1 month, 3 months, 6 months, and 12 months post-treatment — to track clinical outcomes, repeat relevant biomarker panels, adjust lifestyle and supplementation recommendations, and document safety data. [15]

What to look for: Ask the clinic to describe its follow-up protocol in writing before you book. The protocol should specify which assessments will be performed at each follow-up point — clinical examination, laboratory tests, imaging where applicable, and validated outcome-measurement tools relevant to your condition (e.g., WOMAC for knee osteoarthritis, HAQ for rheumatoid arthritis, EDSS for multiple sclerosis).

Clinics that invest in follow-up are clinics that invest in outcomes. They use the data to refine protocols, contribute to clinical knowledge, and improve patient care. Clinics that treat you and send you home with no planned follow-up are interested in the transaction, not the result.

Ask: "What follow-up assessments will you perform at 3 months and 6 months? How will you measure whether the treatment worked for my condition?"

Step 7: Look for Published Research and Clinical Data

Clinics that contribute to the evidence base operate differently from clinics that only extract revenue from it. A responsible clinic conducts outcomes research, publishes case series or clinical studies in peer-reviewed journals, participates in clinical registries, and can share anonymized outcome data for patients with your condition who received similar protocols. [13]

What to look for: Search PubMed for the clinic's name and the names of its lead physicians. A legitimate clinic will have at least some publication record — even if modest — demonstrating engagement with the scientific community. Check ClinicalTrials.gov and the Thai Clinical Trials Registry (TCTR) for registered trials involving the clinic or its physicians. Registration means the study protocol has been reviewed and the investigators have committed to transparency about their methods and results. [14]

Ask the clinic: "Can you share anonymized outcome data for patients with my condition who received the protocol you are recommending?" A legitimate provider should be able to present this — while appropriately acknowledging the limitations and variability inherent in clinical data. An inability or refusal to share any outcome information is inconsistent with evidence-based medical practice.

A Practical Checklist: 10 Questions to Ask Any Clinic

Before booking treatment, every clinic should be able to answer all of the following questions clearly and without hesitation:
  1. Who is the treating physician? — Full name, license number, specialty board, years of MSC-specific experience.
  2. What laboratory processes the cells? — Name, location, accreditations (ISO, GMP), certificate numbers to verify.
  3. Where exactly do the cells come from? — Tissue source, tissue bank, donor screening protocol, batch traceability.
  4. Can I see a Certificate of Analysis for my cell batch? — Viability, cell count, identity markers, sterility, endotoxin levels.
  5. Why this dose and delivery route for my condition? — Published evidence supporting the recommended protocol.
  6. Can I have an itemized cost breakdown? — Cell product cost, physician fees, facility fees, diagnostics, follow-up.
  7. What is the follow-up protocol? — Written schedule with specific assessments at each time point.
  8. What is the adverse event rate and emergency protocol? — Documented safety data and written plan for managing complications.
  9. Can you share published research or outcome data? — PubMed publications, clinical trial registrations, anonymized patient outcomes.
  10. Can I speak with a former patient? — Direct contact with someone who received a similar protocol, not just curated testimonials.

How VELAR Center Measures Up

We publish this guide because we want patients to choose us for the right reasons — because they have done their diligence and found a clinic that meets every standard. At VELAR Center:

Frequently Asked Questions

What is the single most important factor when choosing a stem cell clinic?

The treating physician — their credentials, experience in regenerative medicine, and direct involvement in your care. A licensed, board-certified physician who personally assesses you, designs your protocol, and oversees your treatment is the strongest indicator of a legitimate clinic. If you never meet the physician before treatment day, choose a different clinic.

How can I verify a clinic's accreditations?

Ask for the accreditation certificate number and the name of the issuing body — then verify independently on that body's public registry. ISO certificates can be checked through the national accreditation body that issued them. GMP certifications are verifiable through the relevant national pharmaceutical or health authority. Any legitimate accreditation is a matter of public record.

What should a Certificate of Analysis include?

A proper Certificate of Analysis for a cell therapy product should include cell type and source, total nucleated cell count, viable MSC count (by flow cytometry), viability percentage (>90% is standard), ISCT identity marker expression (positive for CD73, CD90, CD105; negative for CD34, CD45, HLA-DR), sterility testing results, endotoxin levels, and donor infectious disease screening results.

How much does legitimate stem cell therapy cost?

Legitimate GMP-grade MSC therapy typically costs between USD 8,000 and USD 25,000, depending on the condition, cell dose, delivery complexity, and protocol specifics. Prices below USD 3,000 are inconsistent with the cost of producing quality cells. Prices above USD 25,000 may be justified for complex multi-dose protocols but should come with full itemized transparency.

Do I need to travel abroad for stem cell therapy?

Many patients choose international clinics because regulatory frameworks, cell-quality standards, and pricing vary significantly between countries. Thailand, in particular, has emerged as a destination for regenerative medicine due to its combination of international-standard hospitals, GMP-certified laboratories, experienced physician specialists, and costs that are typically lower than in the United States or Europe. The same due diligence applies regardless of destination — verify credentials independently, do not rely on the clinic's website alone.

What follow-up should I expect after MSC therapy?

A responsible clinic schedules structured follow-up at 1, 3, 6, and 12 months post-treatment. At each point, you should receive clinical assessments, relevant laboratory tests, and condition-specific outcome measurements. The follow-up data should be used to refine your ongoing care plan and contributes to the clinic's quality-improvement system.

Limitations and Context

This guide reflects the state of knowledge as of mid-2026. The regulatory landscape for cell-based therapies, accreditation frameworks, and clinical evidence continue to evolve. The selection criteria described here are based on documented patterns of safe and unsafe practices in the peer-reviewed literature and regulatory actions, but they are not exhaustive.

Meeting the criteria in this guide does not eliminate all risk — no medical procedure is risk-free — but it substantially reduces the likelihood of encountering an unsafe operator. A clinic that meets every standard described here is operating at a level of professionalism consistent with evidence-based, patient-centered regenerative medicine.

Patient safety is non-negotiable. Take your time. Ask every question. Verify every answer. A legitimate clinic will welcome the scrutiny — because it has nothing to hide.

References

  1. Sipp D, Caulfield T, Kaye J, et al. Marketing of unproven stem cell-based interventions: a call to action. Science Translational Medicine. 2017;9(397):eaag0426. doi:10.1126/scitranslmed.aag0426 ↩
  2. Turner L. The US direct-to-consumer marketplace for unproven stem cell interventions. Cytotherapy. 2021;23(1):10-17. doi:10.1016/j.jcyt.2020.08.009 ↩
  3. Bauer G, Elsallab M, Abou-El-Enein M. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Translational Medicine. 2018;7(9):676-685. doi:10.1002/sctm.17-0282 ↩
  4. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  5. Master Z, Robertson K, Frederick D, Rachul C, Caulfield T. Stem cell tourism and public education: the missing elements. Cell Stem Cell. 2014;15(3):267-270. doi:10.1016/j.stem.2014.08.009 ↩
  6. Sensebé L, Gadelorge M, Fleury-Cappellesso S. Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review. Stem Cell Research & Therapy. 2013;4(3):56. doi:10.1186/scrt217 ↩
  7. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  8. Bieback K, Brinkmann I. Mesenchymal stromal cells from human perinatal tissues: from biology to cell therapy. World Journal of Stem Cells. 2010;2(4):81-92. doi:10.4252/wjsc.v2.i4.81 ↩
  9. Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019-1024. doi:10.1016/j.jcyt.2019.08.002 ↩
  10. Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal injection of autologous "stem cells" for AMD. New England Journal of Medicine. 2017;376(11):1047-1053. doi:10.1056/NEJMoa1609583 ↩
  11. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  12. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplantation. 2016;25(5):829-848. doi:10.3727/096368915X689622 ↩
  13. Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11-22. doi:10.1016/j.stem.2015.06.007 ↩
  14. Marks PW, Witten CM, Califf RM. Clarifying stem-cell therapy's benefits and risks. New England Journal of Medicine. 2017;376(11):1007-1009. doi:10.1056/NEJMp1613723 ↩
  15. Fung M, Yuan Y, Atkins H, Shi Q, Bubela T. Responsible translation of stem cell research: an assessment of clinical trial registration and publications. Stem Cell Reports. 2017;8(5):1190-1201. doi:10.1016/j.stemcr.2017.03.013 ↩